Taken together, these results suggest that interfering with the PGE2–EP2/EP4 axis in cancer-specific CD8+ T cells can elicit their expansion and effector differentiation within tumours and result in protective T cell-mediated anticancer immunity. The gene discussed is CD8A; the disease is cancer.